immunosuppressive therapy that will control GVHD and maintain anti-leukemic and anti-infectious immunity.
Multi-potent, mesenchymal stromal cells (MSC) prevent T cell proliferation in vitro
and secrete a number of soluble factors that modulate the immune response, including transforming growth factor (TGF)-_ [1] , indoleamine, 2,3-dioxygenase (IDO) [2] and nitric oxide [3] . Clinical exploitation of these cells has yielded mixed results. Several studies have reported striking resolution of steroid-refractory GVHD after MSC infusion [4] [5] [6] [7] , particularly in patients with gut and liver involvement, while a recent phase III clinical trial by Osiris on the treatment of steroid-refractory GVHD reported an overall response to MSC (Prochymal™) that was not different to that of placebo overall (35% treated vs. 30% in controls, n=260) [8] . These reports highlight that while much enthusiasm has surrounded the effectiveness of MSC as a therapeutic for 4 GVHD, further research is required to validate and optimize the use of these cells for anti-GVHD therapy.
One significant problem is that although the immunosuppressive nature of MSC has been delineated in vitro, little is known about their ability to modulate the immune response in vivo. Such studies are likely to help understand how MSC could be most effectively used to suppress immune responses that underlie GVHD while maintaining the anti-leukemic effect of HSCT.
To understand the in vivo effects of MSC, we used murine models of GVHD. We confirmed that our MSC were highly suppressive of T cell proliferation in vitro, however we found that in vivo MSC could delay, but not prevent GVHD. We found that timing and dose of MSC administration was critical for their efficacy and was associated with alteration of the pro-inflammatory cytokine secretion profile. These observations highlight the importance of understanding how MSC mediate their immunomodulatory capacity in vivo if MSC are to be a serious anti-GVHD therapy. GVHD Monitoring: Conditioned and transplanted mice were monitored daily for the onset and severity of GVHD as previously described [10] . Briefly, mice were given a score from 0-2 (or 2.5 in the case of weight loss) for a series of clinical parameters indicative of GVHD including posture (hunching), activity, fur texture, skin and eye integrity and diarrhoea. Any animals that scored 2.0 for either activity or diarrhoea, 2.5 for weight loss or achieved a cumulative score of 8.0 were considered to have severe GVHD. These mice were sacrificed and their organs harvested for analysis.
Design and Methods

Mice
Otherwise mice were monitored for up to 3 months post HSCT and scored in a blinded manner to eliminate bias. At the time of sacrifice we evaluated the effects of 7 MSC on onset and severity of GVHD, donor chimerism, proinflammatory cytokine production, DC, macrophages, granulocytes, B cells, T cells including T-regulatory cells in the BM and spleen using the techniques described below. H&E sections of skin, liver, small and large intestine and lungs were assessed by a pathologist with no knowledge of treatment groups using a scoring system previously described [12] . 
Mixed lymphocyte reaction (MLR):
T-cell proliferation was measured by MLR as previously described [10] . Responder T-cells derived from C57BL/6 were purified using a pan T-cell isolation kit (Miltenyi Biotec, Gladbach Germany). Stimulator cells 
Results
MSC potently suppress T cell proliferation and inflammatory cytokine production in vitro
The suppressive potential of MSC was confirmed in vitro prior to the commencement of in vivo studies. MSC, at a ratio of 1 MSC:100 T cells significantly suppressed T cell proliferation (p<0.001, Figure 1A ). This suppression was further enhanced if the Figure 2E ). This suggests that whilst MSC appear to exert their immunosuppressive effects early post-transplant, they do not have a protective effect on the gut, and consequently do not attenuate weight loss.
Furthermore, these observations also suggest that in this transplant setting, MSC attenuate GVHD via a mechanism that does not directly heal damaged gut tissue.
Assessment of cellular composition of bone marrow ( Figure 2F ) and spleen ( Figure   2G ) at the time of sacrifice did not reveal any significant differences in donor engraftment. Despite MSC-mediated in vitro suppression of T cell proliferation, no differences in the percentage of donor or host T cells, or their subsets were observed in the spleen (or the bone marrow, data not shown) between MSC-treated and control mice ( Figure 2H ). There were also no differences in B cells, granulocytes or macrophages (data not shown). However MSC-treated mice had less mature host DC in the spleen ( Figure 2I , p<0.05) when compared with controls suggesting that MSC may exert their immunosuppressive effects via host DC.
MSC alter the inflammatory milieu early after MHC mismatched HSCT
Given the importance of DC in driving GVHD, we used time course experiments to directly compare differences in engraftment, cellular composition and cytokine secretion in the bone marrow, lymph nodes and spleen between controls or mice treated with MSC 24 hours after HSCT. We found that the cellular composition in bone marrow and spleen remained unchanged between control mice and mice that received MSC. There were also no significant differences in engraftment levels in the bone marrow, spleen or lymph nodes, or in percentages of total T cells ( Figure 3A However, even 24 hours after MSC infusion when the majority of MSC were found (mean 3632 ± 1695 cells), only 0.2% of the MSC infused were accounted for (although only GVHD-target organs were assessed; Figure 4B ). This suggests that when MSC are administered via IP injection they either die, or are dispersed widely throughout the body, the latter hypothesis being supported by other studies [19] [20] [21] .
Other data from our laboratory has shown that intravenous infusion of MSC does not were evaluated for their ability to delay death from GVHD after MHC mismatched HSCT. Transplant recipients that received either Cs alone [11] or KT3 alone survived an average of 11-14 days longer than saline treated controls and 8-11 days longer than MSC-treated mice (Mean survival -Cs: 18.17 ± 3.28 days; KT3: 21.33 ± 3.21 days, controls: 6.67 ± 0.26 days, MSC-treated mice 9.5 ± 1.02 days, Figure 5A ). However we did not observe any further survival advantage when these anti-T cell therapies were used in combination with MSC. These results highlight the efficacy of traditional immunosuppressants and although administered at the optimal time and dose, MSC as therapy for GVHD in this model are significantly less effective (MSC vs. KT3: p<0.01; MSC vs. Cs: p<0.05).
IFN! pre-treatment of MSC does not enhance their efficacy
Although MSC were significantly less effective than KT3 and Cs monotherapy and could not prolong survival when used in combination with these therapies, Polchert et al [12] recently showed that administration of IFN! pre-treated MSC prevented death from GVHD in mice after allogeneic HSCT. We therefore sought to determine if the efficacy of MSC could be enhanced by IFN! pre-treatment in our model. We showed that transplant recipients that received MSC pre-treated for 48 hours with IFN! survived for 10.67±1.38 days, compared to untreated mice that survived a mean of 6.6±0.31 days. Mice treated with un-manipulated MSC survived a mean of 9.5 ± 1.02 days ( Figure 5B ). Administration of IFN! pre-treated MSC to HSCT recipients did not translate to a significant overall increase in survival compared to that seen in mice receiving un-manipulated MSC (p=NS). GVHD scores were not different between groups on day +3, but at day +6 were significantly reduced in both MSC-treated groups compared to controls ( Figure 5D , p<0.05). No differences in weight loss were observed between groups at either day +3 ( Figure 5E ) or day +6 ( Figure 5F ), suggesting that IFN! pre-treatment did not increase the efficacy of MSC in our model. When comparing GVHD scores and weight loss post-transplant in the miHA mismatch model, we observed that early post-transplant (up to day 7), scores and weight loss were similar amongst all groups, suggesting that administration of MSC did not attenuate conditioning-related toxicity. Divergence between controls and MSC-treated mice started from day 18 as reflected in the survival curves, however over time, no obvious differences were observed in either weight loss ( Figure 6D-F) or GVHD scores of either cohort ( Figure 6G-I ).
Effect of MSC after
Given the reduction in serum levels of TNF" and IFN! seen in the MHC mismatched HSCT recipients; we monitored the cytokine milieu that MSC were entering at the time of infusion in miHA HSCT recipients. Blood samples were taken from untreated controls at day +1, day +7 and day +14 to measure T H 1 and T H 2 serum cytokine levels. IFN! showed the most significant fluctuation, rising from virtually undetectable levels at day 1 (mean 1.6 ± 1.34 pg/ml) to a sharp peak at day +7 (409±123.3 pg/ml), and returning to low levels by day +14 post transplant (mean 14.47±4.87 pg/ml, p<0.05, Figure 6J ). TNF" also increased significantly from day +1
(nil detected) to day +7 (mean 112.4±28.6 pg/ml, p<0.05, Figure 6K ) and reduced again by day +14. Levels of IL-5, a potent stimulator of B cell proliferation and differentiation, were increased on day +7 (mean 23.19 ± 1.96 pg/ml, p<0.01) and +14 (21.38 ± 5.99 pg/ml p<0.01) compared to day 1 (6.25l ± 2.19 pg/ml, Figure 6L ).
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MSC show significant immunosuppressive capacity in vitro and infusion of these cells is therefore being trialled as a novel therapy to ameliorate clinical GVHD.
Although this treatment has been reported to be effective in several studies [5, 7, 29, 30 ], a recent trial has questioned their efficacy [8] . Understanding how MSC exert their immunosuppressive effects in clinically relevant in vivo models is essential to evaluate the therapeutic potential of MSC against GVHD. However MSC-mediated control of GVHD is not reliably reproduced in animal models. This may be because MSC are administered as monotherapy in murine models of GVHD using radiation alone as opposed to clinically relevant conditioning regimens; while in the clinic MSC are invariably administered in combination with conventional immunosuppressive drugs such as Cs.
To address this, we used two murine models of GVHD in combination with clinically relevant conditioning (cyclophosphamide + TBI) as the preparative regimen. We found that a single infusion of 4x10 5 MSC (equivalent to 2x10 7 /kg) on day +1 after MHC mismatched HSCT significantly delayed death from GVHD. When we used Cs or T-cell depletion (KT3) alongside MSC, which more accurately replicates a potential clinical scenario, we found that Cs and KT3 were more effective than MSC alone in delaying death from GVHD. In this model, MSC offered no additional survival benefit when they were combined with these traditional therapies, which. The lack of improved efficacy of these combination therapies may be a consequence of When we used the MHC matched, miHA mismatched HSCT model, which replicates HLA-identical allogeneic sibling transplant, similar to our MHC mismatched model, we found that, MSC were most effective at delaying GVHD onset when 4x10 5 MSC/mouse were administered on day +1.
Despite the delay of death from GVHD in our HSCT models, we only observed minimal differences in the cellular composition of the bone marrow and spleen between MSC-treated and control mice. We observed a reduced percentage of mature host DC at the time of death, however this may simply reflect a temporal difference because these DC subsets were not altered between control and MSC-treated mice in timed sacrifice experiments. Interestingly, the percentage of T cells remains unchanged, which highlights differences between the re-created in vitro environment where MSC block T cell proliferation and the in vivo milieu. Clinical studies report that MSC-treated patients experience a higher incidence of relapse [30] and incidence of infection [5] ; our observations suggest that the efficacy of MSC does not appear to be T cell-dependent, allowing us to speculate that MSC will not compromise the beneficial graft-versus-leukaemia effect of the transplant.
The notable observation that may explain why MSC delay GVHD in our murine transplant recipients was that IFN! levels were reduced in the presence of MSC.
Because MSC do not alter the composition of the T cell populations in these HSCT models, these data do not support the hypothesis that MSC are licensed by IFN_ to suppress T cell proliferation but instead the data suggests that MSC may delay GVHD progression by altering the inflammatory milieu. In the MHC matched, miHA mismatched transplant experiments, we observed that MSC were only effective if they were added on day +1, but were not effective if they were added on day +7 or +14.
This may be because the levels of IFN! at these later time points were too great to be Osiris trial despite a sub-analysis which showed that MSC were beneficial to patients with steroid-refractory GVHD involving the gut or liver [31] . These data are in contrast to several other pre-clinical and clinical studies. The significant differences between our study and those which showed a prolonged survival benefit with MSC in pre-clinical models [12, 22, 23, 26, 28] may result from variations in MSC isolation and culture methods; the degree of H-2 disparity between the donor and host and our use of a clinically relevant conditioning regimen. The lack of congruity between our results and the majority of clinical studies [5, 7, 29, 30] , may be due to the fact that MSC are administered to highly immunosuppressed patients and the use of combination therapy may mask the effect of MSC on GVHD suppression and resolution; a variable not taken into consideration in pre-clinical transplant models.
CONCLUSION
Overall we conclude that while MSC may have a clinically relevant role in the attenuation of GVHD, the dose and timing of their administration will directly affect their efficacy. Given the lack of consensus in pre-clinical models and the recent Osiris trial results, further research into elucidation of the mechanism of action is required 22 before MSC become conventional therapy in the allogeneic HSCT setting.
Importantly, our observation of the association of increased systemic IFNy and increased efficacy of MSC-mediated immunosuppression could provide a trigger to define the time patients at risk of GVHD are most likely to benefit from MSC administration.
AUTHORSHIP AND DISCLOSURES
AR was the principal investigator. MC, BT, LS, HC and KK performed the laboratory work. MC and AR were responsible for data analysis, interpretation of results and coordinating the research. MC, AR and NW prepared the manuscript. DH and KA assisted in experimental design.
The authors declare no competing financial interests. Online Supplementary Figure 2 
